Drug intelligence / Profile preview

MCBC

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

The MCBC regimen is a modified dual alkylator-conditioning regimen employed in the pretreatment of refractory or relapsed Acute Myeloid Leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This regimen combines the chemotherapeutic agents Melphalan, Cladribine, Busulfan, and Cyclophosphamide. Its primary objective is to effectively eradicate leukemia blasts and mitigate the risk of early relapse, demonstrating significant anti-leukemia activity with manageable toxicity.

Targets

DNA

Beyond the preview

Go deeper on MCBC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCBC.

Explore the full profile